Drug facts
MoleculeFenofibrate
Generics already compete: 26 makers on the market. 80 A-rated products from 25 makers substitute at the counter.
Lipidil was first approved by the FDA on 12/31/1993 under NDA 019304; the application holder is Abbvie Inc. The Orange Book lists NDA 019304 as discontinued.
The latest NADAC for FENOFIBRATE 43 MG CAPSULE is $0.40 per unit (as of 10/28/2026).
Holder Abbvie IncApplication NDA 019304Approved 12/31/1993
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Lipidil patent listed in the Orange Book Orange Book
- Later patents, other products
- Antara 05/31/2033 Orange Book
02Competition
- Generics
- 26 generic makers Orange Book
- First generic approved
- 04/09/2002 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Fenofibrate profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.40 per unitFENOFIBRATE 43 MG CAPSULE, mid-priced of 7 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 05/28/2026Class II, Fenofibrate, Ajanta Pharma USA Inc FDA enforcement
04Product
- Application holder
- Abbvie Inc Orange Book
- Application
- NDA 019304 Orange Book
- First approved
- 12/31/1993 Orange Book
- Dosage forms
- capsule; tablet
- Routes
- oral
- Other brand names
- AntaraLipofen
- Status
- NDA 019304 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.